{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:38:50Z","timestamp":1793039930934,"version":"4.5.0"},"reference-count":238,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P20GM135000"],"award-info":[{"award-number":["P20GM135000"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P20GM130555"],"award-info":[{"award-number":["P20GM130555"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006952","name":"Louisiana Board of Regents","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006952","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20GM103424"],"award-info":[{"award-number":["P20GM103424"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.omton.2025.201100","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T23:44:08Z","timestamp":1763855048000},"page":"201100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Viral warriors: Unlocking the immune system\u2019s potential with oncolytic viruses in cancer immunotherapy"],"prefix":"10.1016","volume":"33","author":[{"given":"Reza","family":"Ghavimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Rahimian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ojasvi","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harikrishnan","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Chouljenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tolulope O.","family":"Omolekan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Christopher","family":"Chamcheu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7077-9003","authenticated-orcid":false,"given":"Konstantin G.","family":"Kousoulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2025.201100_bib1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4103\/RPS.RPS_75_24","article-title":"Exploring the potential of anticancer peptides as therapeutic agents for cancer treatment","volume":"20","author":"Ghavimi","year":"2025","journal-title":"Res. Pharm. Sci."},{"key":"10.1016\/j.omton.2025.201100_bib2","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1186\/s12885-024-13035-6","article-title":"Estimation of burden of cancer incidence and mortality in India: based on global burden of disease study 1990\u20132021","volume":"24","author":"Jena","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.omton.2025.201100_bib3","unstructured":"Danjuma, A.I., and Daniel, E.O. Knowledge, Attitude, and Practice of Cervical Cancer Screening Among Female Youth in Jabi District, Abuja Municipal Area Council, Nigeria."},{"key":"10.1016\/j.omton.2025.201100_bib4","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1007\/s10989-021-10275-z","article-title":"Production and Evaluation of In-vitro and In-vivo Effects of P28-IL24, a Promising Anti-breast Cancer Fusion Protein","volume":"27","author":"Ghavimi","year":"2021","journal-title":"Int. J. Pept. Res. Ther."},{"key":"10.1016\/j.omton.2025.201100_bib5","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1007\/s10989-021-10260-6","article-title":"Characterization of antitumor activity of a synthetic moronecidin-like peptide computationally predicted from the tiger tail seahorse hippocampus comes in tumor-bearing mice","volume":"27","author":"Ghasemi","year":"2021","journal-title":"Int. J. Pept. Res. Ther."},{"key":"10.1016\/j.omton.2025.201100_bib6","series-title":"T Cell Metabolism and Cancer Immunotherapy","first-page":"235","article-title":"Oncolytic virus for cancer immunotherapy","author":"Yang","year":"2025"},{"key":"10.1016\/j.omton.2025.201100_bib7","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.3390\/v15112262","article-title":"Tumor tropism of DNA viruses for oncolytic virotherapy","volume":"15","author":"Enow","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.omton.2025.201100_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1082797","article-title":"Comprehensive assessment on the applications of oncolytic viruses for cancer immunotherapy","volume":"13","author":"Omole","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.omton.2025.201100_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1618751","article-title":"Viral Warfare: Unleashing Engineered Oncolytic Viruses to Outsmart Cancer's Defenses","volume":"16","author":"Omolekan","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2025.201100_bib10","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-020-00922-1","article-title":"Oncolytic viruses for cancer immunotherapy","volume":"13","author":"Hemminki","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omton.2025.201100_bib11","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.3390\/v13081637","article-title":"Rational Design of Live-Attenuated Vaccines against Herpes Simplex Viruses","volume":"13","author":"Stanfield","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.omton.2025.201100_bib12","series-title":"Translational Medicine","first-page":"421","article-title":"Nonclinical Development of Anticancer Biotherapeutics","author":"Todd","year":"2021"},{"key":"10.1016\/j.omton.2025.201100_bib13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3171\/2023.6.JNS23243","article-title":"Oncolytic viral therapy: A review and promising future directions","volume":"140","author":"Reddy","year":"2023","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.omton.2025.201100_bib14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.biochi.2022.10.008","article-title":"History of how viruses can fight cancer: From the miraculous healings to the approval of oncolytic viruses","volume":"206","author":"Bifulco","year":"2023","journal-title":"Biochimie"},{"key":"10.1016\/j.omton.2025.201100_bib15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2165\/00063030-200216020-00001","article-title":"Adenoviruses in oncology: a viable option?","volume":"16","author":"Hemminki","year":"2002","journal-title":"BioDrugs"},{"key":"10.1016\/j.omton.2025.201100_bib16","article-title":"Advances in preclinical and clinical studies of oncolytic virus combination therapy","volume":"15","author":"Du","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2025.201100_bib17","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1126\/science.1851332","article-title":"Experimental therapy of human glioma by means of a genetically engineered virus mutant","volume":"252","author":"Martuza","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.omton.2025.201100_bib18","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s11912-018-0729-3","article-title":"The role of oncolytic viruses in the treatment of melanoma","volume":"20","author":"Bayan","year":"2018","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.omton.2025.201100_bib19","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2174\/1568009618666171129221503","article-title":"Oncorine, the world first oncolytic virus medicine and its update in China","volume":"18","author":"Liang","year":"2018","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.omton.2025.201100_bib20","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1200\/JCO.2015.62.5244","article-title":"Oncolytic virus-mediated immunotherapy: a combinatorial approach for cancer treatment","volume":"33","author":"Lawler","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2025.201100_bib21","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s40588-019-00134-3","article-title":"Anti-viral immunity in the tumor microenvironment: implications for the rational design of herpes simplex virus type 1 oncolytic virotherapy","volume":"6","author":"Rider","year":"2019","journal-title":"Curr. Clin. Microbiol. Rep."},{"key":"10.1016\/j.omton.2025.201100_bib22","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s11912-024-01611-9","article-title":"Talimogene laherparepvec (T-Vec) and emerging intralesional immunotherapies for metastatic melanoma: a review","volume":"26","author":"Kalsi","year":"2024","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.omton.2025.201100_bib23","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3390\/v15020367","article-title":"Inactivation of the UL37 Deamidase Enhances Virus Replication and Spread of the HSV-1 (VC2) Oncolytic Vaccine Strain and Secretion of GM-CSF","volume":"15","author":"Clark","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.omton.2025.201100_bib24","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40265-023-01846-z","article-title":"Nadofaragene firadenovec: First approval","volume":"83","author":"Lee","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.omton.2025.201100_bib25","doi-asserted-by":"crossref","first-page":"S1236","DOI":"10.1016\/j.annonc.2024.08.2287","article-title":"LBA46 Primary efficacy, safety, and survival data from the registration-intended cohort of patients with anti\u2013PD-1\u2013failed melanoma from the IGNYTE clinical trial with RP1 combined with nivolumab","volume":"35","author":"Robert","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.omton.2025.201100_bib26","series-title":"Efficacy and Safety of RP1 Combined with Nivolumab in Patients with Anti\u2013PD-1\u2013failed Melanoma from the IGNYTE Clinical Trial","author":"Wong","year":"2024"},{"key":"10.1016\/j.omton.2025.201100_bib27","doi-asserted-by":"crossref","first-page":"5582","DOI":"10.3390\/cimb46060334","article-title":"Targeting Cancers with oHSV-Based Oncolytic Viral Immunotherapy","volume":"46","author":"Nasar","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.omton.2025.201100_bib28","article-title":"Extracellular matrix re-normalization to improve cold tumor penetration by oncolytic viruses","volume":"15","author":"Soko","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2025.201100_bib29","article-title":"Immunogenic cell death: The cornerstone of oncolytic viro-immunotherapy","volume":"13","author":"Palanivelu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2025.201100_bib30","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3390\/biomedicines13010108","article-title":"Oncolytic Viruses and Immunotherapy for the Treatment of Uveal Melanoma and Retinoblastoma: The Current Landscape and Novel Advances","volume":"13","author":"Kulbay","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.omton.2025.201100_bib31","doi-asserted-by":"crossref","first-page":"543","DOI":"10.30574\/wjarr.2024.21.1.2585","article-title":"Modulating the immunosuppressive tumor microenvironment: Multi-synergistic cancer therapeutic approach with oncolytic viruses","volume":"21","author":"Bayode","year":"2024","journal-title":"World J. Adv. Res. Rev."},{"key":"10.1016\/j.omton.2025.201100_bib32","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.3390\/v13071271","article-title":"Combinatorial approaches for cancer treatment using oncolytic viruses: projecting the perspectives through clinical trials outcomes","volume":"13","author":"Malogolovkin","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.omton.2025.201100_bib33","doi-asserted-by":"crossref","first-page":"4827","DOI":"10.1128\/JVI.77.8.4827-4835.2003","article-title":"Complexes of poliovirus serotypes with their common cellular receptor, CD155","volume":"77","author":"He","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2025.201100_bib34","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1126\/science.1553561","article-title":"Identification of the integrin VLA-2 as a receptor for echovirus 1","volume":"255","author":"Bergelson","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.omton.2025.201100_bib35","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1158\/0008-5472.CAN-04-0884","article-title":"High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus","volume":"64","author":"Anderson","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2025.201100_bib36","series-title":"Enhanced cellular uptake of virus by increased expression levels of the coxsackie-and adenovirus receptor (SLU, Dept. of Biomedical Sciences and Veterinary Public Health (until 231231))","author":"Lindstr\u00f6m","year":"2005"},{"key":"10.1016\/j.omton.2025.201100_bib37","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3390\/v8090250","article-title":"The host cell receptors for measles virus and their interaction with the viral hemagglutinin (H) protein","volume":"8","author":"Lin","year":"2016","journal-title":"Viruses"},{"key":"10.1016\/j.omton.2025.201100_bib38","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.exphem.2006.03.002","article-title":"Oncolytic measles virus targets high CD46 expression on multiple myeloma cells","volume":"34","author":"Ong","year":"2006","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.omton.2025.201100_bib39","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1365-2141.2007.06550.x","article-title":"Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma","volume":"137","author":"Au","year":"2007","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.omton.2025.201100_bib40","doi-asserted-by":"crossref","first-page":"6015","DOI":"10.1128\/JVI.01537-10","article-title":"Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells","volume":"85","author":"Mansour","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2025.201100_bib41","first-page":"1","article-title":"Novel Therapies in Glioblastoma Treatment: Review of Glioblastoma; Current Treatment Options; and Novel Oncolytic Viral Therapies","volume":"12","author":"Shah","year":"2023","journal-title":"Med. Sci."},{"key":"10.1016\/j.omton.2025.201100_bib42","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1128\/JVI.01896-07","article-title":"Modification of adenovirus capsid with a designed protein ligand yields a gene vector targeted to a major molecular marker of cancer","volume":"82","author":"Belousova","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2025.201100_bib43","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.3390\/v2102290","article-title":"Tropism-modification strategies for targeted gene delivery using adenoviral vectors","volume":"2","author":"Coughlan","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.omton.2025.201100_bib44","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3390\/v10070352","article-title":"HSV as a platform for the generation of retargeted, armed, and reporter-expressing oncolytic viruses","volume":"10","author":"Menotti","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.omton.2025.201100_bib45","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/gt.2016.17","article-title":"Development of an oncolytic HSV vector fully retargeted specifically to cellular EpCAM for virus entry and cell-to-cell spread","volume":"23","author":"Shibata","year":"2016","journal-title":"Gene Ther."},{"key":"10.1016\/j.omton.2025.201100_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2022.198979","article-title":"Construction of an IL12 and CXCL11 armed oncolytic herpes simplex virus using the CRISPR\/Cas9 system for colon cancer treatment","volume":"323","author":"Zhang","year":"2023","journal-title":"Virus Res."},{"key":"10.1016\/j.omton.2025.201100_bib47","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s12935-021-01972-2","article-title":"Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy","volume":"21","author":"Zhang","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.omton.2025.201100_bib48","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2008","article-title":"Defects in interferon pathways as potential biomarkers of sensitivity to oncolytic viruses","volume":"28","author":"Matveeva","year":"2018","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.omton.2025.201100_bib49","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/978-1-61779-340-0_12","article-title":"Exploring host factors that impact reovirus replication, dissemination, and reovirus-induced cell death in cancer versus normal cells in culture","volume":"797","author":"Shmulevitz","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.omton.2025.201100_bib50","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3390\/jcm9010171","article-title":"Oncolytic virotherapy with myxoma virus","volume":"9","author":"Rahman","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.omton.2025.201100_bib51","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.trecan.2015.10.004","article-title":"Oncolytic viruses: exploiting cancer's deal with the devil","volume":"1","author":"Pikor","year":"2015","journal-title":"Trends Cancer"},{"key":"10.1016\/j.omton.2025.201100_bib52","doi-asserted-by":"crossref","DOI":"10.1038\/srep30846","article-title":"Pyruvate dehydrogenase kinase regulates hepatitis C virus replication","volume":"6","author":"Jung","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omton.2025.201100_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0098032","article-title":"Diisopropylamine dichloroacetate, a novel pyruvate dehydrogenase kinase 4 inhibitor, as a potential therapeutic agent for metabolic disorders and multiorgan failure in severe influenza","volume":"9","author":"Yamane","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.omton.2025.201100_bib54","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.3390\/v13071200","article-title":"The effect of herpes simplex virus-type-1 (HSV-1) oncolytic immunotherapy on the tumor microenvironment","volume":"13","author":"Uche","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.omton.2025.201100_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107271","article-title":"Dual inhibitors of DNMT and HDAC remodels the immune microenvironment of colorectal cancer and enhances the efficacy of anti-PD-L1 therapy","volume":"206","author":"Yang","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.omton.2025.201100_bib56","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3390\/cancers16050984","article-title":"Impact of complex apoptotic signaling pathways on cancer cell sensitivity to therapy","volume":"16","author":"Kim","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.omton.2025.201100_bib57","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3389\/fcell.2020.00047","article-title":"Regulation of autophagy in cells infected with oncogenic human viruses and its impact on cancer development","volume":"8","author":"Vescovo","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.omton.2025.201100_bib58","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.omton.2025.201100_bib59","doi-asserted-by":"crossref","DOI":"10.1002\/adtp.202300445","article-title":"Oncolytic Viruses in Cancer Immunotherapy","volume":"7","author":"Li","year":"2024","journal-title":"Adv. Therapeut."},{"key":"10.1016\/j.omton.2025.201100_bib60","series-title":"Unraveling the Phenotypic Features and Functional Mechanisms of Tumor-Associated Adaptive Natural Killer Cells","author":"Sun","year":"2025"},{"key":"10.1016\/j.omton.2025.201100_bib61","article-title":"Induction of immunogenic tumor cell death by attenuated oncolytic measles virus","volume":"6","author":"Achard","year":"2015","journal-title":"J. Clin. Cell. Immunol."},{"key":"10.1016\/j.omton.2025.201100_bib62","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/mt.2013.220","article-title":"Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies","volume":"22","author":"Workenhe","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2025.201100_bib63","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.omton.2025.201100_bib64","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nrc3380","article-title":"Immunogenic cell death and DAMPs in cancer therapy","volume":"12","author":"Krysko","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omton.2025.201100_bib65","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3390\/v5020470","article-title":"Learning from the messengers: innate sensing of viruses and cytokine regulation of immunity\u2014clues for treatments and vaccines","volume":"5","author":"Melchjorsen","year":"2013","journal-title":"Viruses"},{"key":"10.1016\/j.omton.2025.201100_bib66","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3389\/fonc.2014.00074","article-title":"Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity","volume":"4","author":"Guo","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2025.201100_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2021.198440","article-title":"Oncolytic reovirus induces ovarian cancer cell apoptosis in a TLR3-dependent manner","volume":"301","author":"An","year":"2021","journal-title":"Virus Res."},{"key":"10.1016\/j.omton.2025.201100_bib68","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.it.2017.11.006","article-title":"Antitumor benefits of antiviral immunity: an underappreciated aspect of oncolytic virotherapies","volume":"39","author":"Gujar","year":"2018","journal-title":"Trends Immunol."},{"key":"10.1016\/j.omton.2025.201100_bib69","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.omton.2025.201100_bib70","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","article-title":"Integrating oncolytic viruses in combination cancer immunotherapy","volume":"18","author":"Bommareddy","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.omton.2025.201100_bib71","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omton.2025.201100_bib72","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1591875","article-title":"Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma","volume":"8","author":"Bommareddy","year":"2019","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omton.2025.201100_bib73","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1089\/10430349950018832","article-title":"Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity","volume":"10","author":"Toda","year":"1999","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omton.2025.201100_bib74","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1158\/0008-5472.CAN-06-3974","article-title":"Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus","volume":"67","author":"Diaz","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2025.201100_bib75","doi-asserted-by":"crossref","first-page":"7358","DOI":"10.1158\/1078-0432.CCR-08-0831","article-title":"Tumor infection by oncolytic reovirus primes adaptive antitumor immunity","volume":"14","author":"Prestwich","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2025.201100_bib76","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41568-018-0009-4","article-title":"Oncolytic viruses as engineering platforms for combination immunotherapy","volume":"18","author":"Twumasi-Boateng","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omton.2025.201100_bib77","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1158\/1078-0432.CCR-18-3200","article-title":"Biological consequences of MHC-II expression by tumor cells in cancer","volume":"25","author":"Axelrod","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2025.201100_bib78","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3389\/fonc.2014.00077","article-title":"Oncolytic virus-mediated reversal of impaired tumor antigen presentation","volume":"4","author":"Gujar","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2025.201100_bib79","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01447","article-title":"Mixed signals: co-stimulation in invariant natural killer T cell-mediated cancer immunotherapy","volume":"8","author":"Shissler","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2025.201100_bib80","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1158\/1535-7163.MCT-10-0590","article-title":"Reovirus virotherapy overrides tumor antigen presentation evasion and promotes protective antitumor immunity","volume":"9","author":"Gujar","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.omton.2025.201100_bib81","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1726168","article-title":"Tumor-targeting oncolytic virus elicits potent immunotherapeutic vaccine responses to tumor antigens","volume":"9","author":"Luo","year":"2020","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omton.2025.201100_bib82","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/mt.2010.297","article-title":"Oncolytic virus-initiated protective immunity against prostate cancer","volume":"19","author":"Gujar","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2025.201100_bib83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jtbi.2015.04.004","article-title":"Memory versus effector immune responses in oncolytic virotherapies","volume":"377","author":"Macnamara","year":"2015","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.omton.2025.201100_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.108103","article-title":"Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment","volume":"236","author":"Feola","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.omton.2025.201100_bib85","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.imlet.2014.02.009","article-title":"Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy","volume":"159","author":"Bai","year":"2014","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.omton.2025.201100_bib86","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s40425-019-0664-3","article-title":"Molecular and metabolic pathways mediating curative treatment of a non-Hodgkin B cell lymphoma by Sindbis viral vectors and anti-4-1BB monoclonal antibody","volume":"7","author":"Yu","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2025.201100_bib87","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001486","article-title":"Clinical landscape of oncolytic virus research in 2020","volume":"8","author":"Macedo","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2025.201100_bib88","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1186\/s12967-023-04360-8","article-title":"Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy","volume":"21","author":"Wang","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.omton.2025.201100_bib89","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/978-1-4419-1132-2_10","article-title":"HSV as a vector in vaccine development and gene therapy","volume":"655","author":"Marconi","year":"2009","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.omton.2025.201100_bib90","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2174\/156800907780058880","article-title":"Oncolytic viruses driven by tumor-specific promoters","volume":"7","author":"Hardcastle","year":"2007","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.omton.2025.201100_bib91","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/978-981-10-7230-7_4","article-title":"Oncolytic virotherapy by HSV","volume":"1045","author":"Watanabe","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.omton.2025.201100_bib92","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40883-023-00295-0","article-title":"Extracellular Vesicles: A Trojan Horse Delivery Method for Systemic Administration of Oncolytic Viruses","volume":"9","author":"Taheri","year":"2023","journal-title":"Regen. Eng. Transl. Med."},{"key":"10.1016\/j.omton.2025.201100_bib93","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.3390\/ijms24054422","article-title":"Tumor vasculature as an emerging pharmacological target to promote anti-tumor immunity","volume":"24","author":"Tzeng","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omton.2025.201100_bib94","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1091554","article-title":"CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy","volume":"5","author":"Liu","year":"2016","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omton.2025.201100_bib95","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.2147\/DDDT.S308578","article-title":"Clinical application of cytokines in cancer immunotherapy","volume":"15","author":"Qiu","year":"2021","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.omton.2025.201100_bib96","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1756-9966-31-51","article-title":"Oncolytic adenovirus armed with IL-24 inhibits the growth of breast cancer in vitro and in vivo","volume":"31","author":"Zhu","year":"2012","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.omton.2025.201100_bib97","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13046-015-0131-z","article-title":"Oncolytic tanapoxvirus expressing FliC causes regression of human colorectal cancer xenografts in nude mice","volume":"34","author":"Conrad","year":"2015","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.omton.2025.201100_bib98","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1089\/hum.2014.069","article-title":"Immunological effects of a tumor necrosis factor Alpha\u2013Armed oncolytic adenovirus","volume":"26","author":"Hirvinen","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omton.2025.201100_bib99","doi-asserted-by":"crossref","first-page":"16001","DOI":"10.1038\/mto.2016.1","article-title":"Oncolytic vesicular stomatitis virus expressing interferon-\u03c3 has enhanced therapeutic activity","volume":"3","author":"Bourgeois-Daigneault","year":"2016","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omton.2025.201100_bib100","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.canlet.2016.01.025","article-title":"Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9","volume":"372","author":"Deng","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.omton.2025.201100_bib101","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1158\/1078-0432.CCR-18-1932","article-title":"Tumor microenvironment remodeling by intratumoral oncolytic vaccinia virus enhances the efficacy of immune-checkpoint blockade","volume":"25","author":"Chon","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2025.201100_bib102","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-12-2546","article-title":"Antiviral and antitumor T-cell immunity in patients treated with GM-CSF\u2013coding oncolytic adenovirus","volume":"19","author":"Kanerva","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2025.201100_bib103","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1038\/gt.2010.100","article-title":"Second-generation HIF-activated oncolytic adenoviruses with improved replication, oncolytic, and antitumor efficacy","volume":"17","author":"Cherry","year":"2010","journal-title":"Gene Ther."},{"key":"10.1016\/j.omton.2025.201100_bib104","article-title":"A novel oncolytic herpes simplex virus type 2 has potent anti-tumor activity","volume":"9","author":"Zhao","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.omton.2025.201100_bib105","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002224","article-title":"Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I\/II clinical trial","volume":"9","author":"Zhang","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2025.201100_bib106","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1199068","volume":"10","author":"Nabi","year":"2023","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.omton.2025.201100_bib107","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.70220","article-title":"The Novel Oncolytic Herpes Simplex Virus Type-1 (HSV-1) Vaccine Strain VC2 Constitutively Expressing GM-CSF Causes Increased Intratumoral T Cell Infiltration and Inhibition of Tumor Metastasis in the 4T1\/Balb\/c Mouse Model of Stage Four Breast Cancer","volume":"97","author":"Nabi","year":"2025","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.omton.2025.201100_bib108","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109890","article-title":"A single intramuscular vaccination of mice with the HSV-1 VC2 virus with mutations in the glycoprotein K and the membrane protein UL20 confers full protection against lethal intravaginal challenge with virulent HSV-1 and HSV-2 strains","volume":"9","author":"Stanfield","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.omton.2025.201100_bib109","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/1743-422X-10-317","article-title":"Single dose of glycoprotein K (gK)-deleted HSV-1 live-attenuated virus protects mice against lethal vaginal challenge with HSV-1 and HSV-2 and induces lasting T cell memory immune responses","volume":"10","author":"Iyer","year":"2013","journal-title":"Virol. J."},{"key":"10.1016\/j.omton.2025.201100_bib110","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1128\/JVI.02468-15","article-title":"Deletion of a predicted \u03b2-sheet domain within the amino terminus of herpes simplex virus glycoprotein K conserved among alphaherpesviruses prevents virus entry into neuronal axons","volume":"90","author":"Jambunathan","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2025.201100_bib111","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01359-20","article-title":"Novel oncolytic herpes simplex virus 1 VC2 promotes long-lasting, systemic anti-melanoma tumor immune responses and increased survival in an immunocompetent B16F10-derived mouse melanoma model","volume":"95","author":"Uche","year":"2021","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2025.201100_bib112","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0228252","article-title":"Intramuscular vaccination of mice with the human herpes simplex virus type-1 (HSV-1) VC2 vaccine, but not its parental strain HSV-1 (F) confers full protection against lethal ocular HSV-1 (McKrae) pathogenesis","volume":"15","author":"Naidu","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.omton.2025.201100_bib113","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1016\/j.vaccine.2018.03.075","article-title":"Intramuscular vaccination of guinea pigs with the live-attenuated human herpes simplex vaccine VC2 stimulates a transcriptional profile of vaginal Th17 and regulatory Tr1 responses","volume":"36","author":"Stanfield","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.omton.2025.201100_bib114","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.vaccine.2016.12.018","article-title":"Vaccination of rhesus macaques with the live-attenuated HSV-1 vaccine VC2 stimulates the proliferation of mucosal T cells and germinal center responses resulting in sustained production of highly neutralizing antibodies","volume":"35","author":"Stanfield","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.omton.2025.201100_bib115","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.vaccine.2018.11.042","article-title":"The HSV-1 live attenuated VC2 vaccine provides protection against HSV-2 genital infection in the guinea pig model of genital herpes","volume":"37","author":"Bernstein","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.omton.2025.201100_bib116","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.832393","article-title":"Utility of a Recombinant HSV-1 Vaccine Vector for Personalized Cancer Vaccines","volume":"9","author":"Uche","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.omton.2025.201100_bib117","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1395997","article-title":"Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines","volume":"7","author":"Moon","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omton.2025.201100_bib118","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.ymthe.2005.12.011","article-title":"Immune gene\u2013viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-\u03b3 gene yields efficient antitumor activity in immunodeficient and immunocompetent mice","volume":"13","author":"Su","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2025.201100_bib119","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.surg.2015.01.006","article-title":"Oncolytic adenovirus expressing interferon alpha in a syngeneic Syrian hamster model for the treatment of pancreatic cancer","volume":"157","author":"LaRocca","year":"2015","journal-title":"Surgery"},{"key":"10.1016\/j.omton.2025.201100_bib120","article-title":"GM-CSF and IL-21-armed oncolytic vaccinia virus significantly enhances anti-tumor activity and synergizes with anti-PD1 immunotherapy in pancreatic cancer","volume":"15","author":"Xuan","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2025.201100_bib121","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1158\/0008-5472.CAN-21-0035","article-title":"An oncolytic virus expressing IL15\/IL15R\u03b1 combined with off-the-shelf EGFR-CAR NK cells targets glioblastoma","volume":"81","author":"Ma","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2025.201100_bib122","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.ymthe.2024.12.017","article-title":"Single-cell data-driven design of armed oncolytic virus to boost cooperative innate-adaptive immunity against cancer","volume":"33","author":"Zhao","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2025.201100_bib123","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1470-2045(08)70107-4","article-title":"Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial","volume":"9","author":"Park","year":"2008","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omton.2025.201100_bib124","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3390\/biomedicines9040419","article-title":"Oncolytic virotherapy for cancer: clinical experience","volume":"9","author":"Chaurasiya","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.omton.2025.201100_bib125","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature10358","article-title":"Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans","volume":"477","author":"Breitbach","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.omton.2025.201100_bib126","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007552","article-title":"ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment","volume":"11","author":"Ponce","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2025.201100_bib127","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12967-023-04817-w","article-title":"Recent advances of engineered oncolytic viruses-based combination therapy for liver cancer","volume":"22","author":"Zhang","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.omton.2025.201100_bib128","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.ijbiomac.2022.09.129","article-title":"A concise review of VEGF, PDGF, FGF, Notch, angiopoietin, and HGF signalling in tumor angiogenesis with a focus on alternative approaches and future directions","volume":"221","author":"Vimalraj","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.omton.2025.201100_bib129","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1126\/science.295.5563.2198","article-title":"Setbacks for endostatin","volume":"295","author":"Marshall","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.omton.2025.201100_bib130","article-title":"Enhanced antitumor efficacy of an oncolytic herpes simplex virus expressing an endostatin\u2013angiostatin fusion gene in human glioblastoma stem cell xenografts","volume":"9","author":"Zhang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.omton.2025.201100_bib131","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1158\/1535-7163.MCT-18-0799","article-title":"Oncolytic herpes virus armed with vasculostatin in combination with bevacizumab abrogates glioma invasion via the CCN1 and AKT signaling pathways","volume":"18","author":"Tomita","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.omton.2025.201100_bib132","series-title":"Targeted Drug Delivery","first-page":"155","article-title":"Gene-directed enzyme\u2013prodrug therapy (GDEPT) as a suicide gene therapy modality for cancer treatment","author":"Kharkar","year":"2022"},{"key":"10.1016\/j.omton.2025.201100_bib133","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s41231-023-00144-w","article-title":"Oncolytic virus-based suicide gene therapy for cancer treatment: a perspective of the clinical trials conducted at Henry Ford Health","volume":"8","author":"Thoidingjam","year":"2023","journal-title":"Transl. Med. Commun."},{"key":"10.1016\/j.omton.2025.201100_bib134","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omto.2019.03.005","article-title":"The enhanced tumor specificity of TG6002, an armed oncolytic vaccinia virus deleted in two genes involved in nucleotide metabolism","volume":"14","author":"Foloppe","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omton.2025.201100_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2024.189110","article-title":"A review exploring the fusion of oncolytic viruses and cancer immunotherapy: An innovative strategy in the realm of cancer treatment","volume":"1879","author":"Chattopadhyay","year":"2024","journal-title":"Biochim. Biophys. Acta. Rev. Cancer"},{"key":"10.1016\/j.omton.2025.201100_bib136","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s12032-023-02078-7","article-title":"TRAIL-mediated signaling in bladder cancer: realization of clinical efficacy of TRAIL-based therapeutics in medical oncology","volume":"40","author":"Farooqi","year":"2023","journal-title":"Med. Oncol."},{"key":"10.1016\/j.omton.2025.201100_bib137","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01530","article-title":"Multiple interactions between cancer cells and the tumor microenvironment modulate TRAIL signaling: implications for TRAIL receptor targeted therapy","volume":"10","author":"De Looff","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2025.201100_bib138","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1002\/jmv.26419","article-title":"The recombinant Newcastle disease virus Anhinga strain expressing human TRAIL exhibit antitumor effects on a glioma nude mice model","volume":"93","author":"He","year":"2021","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.omton.2025.201100_bib139","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1038\/cddis.2010.95","article-title":"Efficacy of adenovirally expressed soluble TRAIL in human glioma organotypic slice culture and glioma xenografts","volume":"2","author":"Liu","year":"2011","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.omton.2025.201100_bib140","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/17425247.2019.1617269","article-title":"Achieving systemic delivery of oncolytic viruses","volume":"16","author":"Hill","year":"2019","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.omton.2025.201100_bib141","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s40425-018-0458-z","article-title":"Oncolytic virus immunotherapy: future prospects for oncology","volume":"6","author":"Raja","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2025.201100_bib142","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.trecan.2023.03.009","article-title":"Mouse models for immuno-oncology","volume":"9","author":"Bosenberg","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.omton.2025.201100_bib143","first-page":"285","article-title":"Preclinical Models of Solid Cancers for Testing Cancer Immunotherapies","volume":"9","author":"Exposito","year":"2025","journal-title":"Annu. Rev. Cell Biol."},{"key":"10.1016\/j.omton.2025.201100_bib144","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.3390\/cancers15112989","article-title":"Modeling the tumor microenvironment and cancer immunotherapy in next-generation humanized mice","volume":"15","author":"Chen","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.omton.2025.201100_bib145","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1308890","article-title":"Oncolytic virotherapy in cancer treatment: challenges and optimization prospects","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2025.201100_bib146","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.3389\/fimmu.2020.01423","article-title":"From cancer to immune-mediated diseases and tolerance induction: lessons learned from immune oncology and classical anti-cancer treatment","volume":"11","author":"Kl\u00f6\u00df","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2025.201100_bib147","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1200\/PO.20.00395","article-title":"Evolving role of oncolytic virotherapy: challenges and prospects in clinical practice","volume":"5","author":"Moaven","year":"2021","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.omton.2025.201100_bib148","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.omto.2019.10.007","article-title":"Oncolytic viruses for cancer therapy: barriers and recent advances","volume":"15","author":"Zheng","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omton.2025.201100_bib149","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.2217\/fon-2022-0440","article-title":"Oncolytic viruses: challenges and considerations in an evolving clinical landscape","volume":"18","author":"Lauer","year":"2022","journal-title":"Future Oncol."},{"key":"10.1016\/j.omton.2025.201100_bib150","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2020.100639","article-title":"Oncolytic virotherapy: Challenges and solutions","volume":"45","author":"Goradel","year":"2021","journal-title":"Curr. Probl. Cancer"},{"key":"10.1016\/j.omton.2025.201100_bib151","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3390\/v16050770","article-title":"Integrin-targeting strategies for Adenovirus gene therapy","volume":"16","author":"Nemerow","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.omton.2025.201100_bib152","article-title":"Development and application of oncolytic viruses as the nemesis of tumor cells","volume":"14","author":"Zhu","year":"2023","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.omton.2025.201100_bib153","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113822","article-title":"Formulation-optimized oncolytic viruses: Advancing systemic delivery and immune amplification","volume":"383","author":"Ma","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.omton.2025.201100_bib154","doi-asserted-by":"crossref","first-page":"106","DOI":"10.4236\/ym.2021.52011","article-title":"Oncolytic engineering of ICP34. 5 and LAT of herpes simplex virus type 1","volume":"5","author":"Cai","year":"2021","journal-title":"Yangtze Med."},{"key":"10.1016\/j.omton.2025.201100_bib155","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.coviro.2015.03.016","article-title":"Pexa-Vec double agent engineered vaccinia: oncolytic and active immunotherapeutic","volume":"13","author":"Breitbach","year":"2015","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.omton.2025.201100_bib156","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/sj.mt.6300321","article-title":"Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide","volume":"16","author":"Kreppel","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2025.201100_bib157","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jconrel.2007.06.010","article-title":"Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration","volume":"122","author":"Gao","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.omton.2025.201100_bib158","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.3390\/v13071300","article-title":"Genetic and chemical capsid modifications of adenovirus vectors to modulate vector\u2013host interactions","volume":"13","author":"Weklak","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.omton.2025.201100_bib159","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/cgt.2009.44","article-title":"Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination","volume":"17","author":"Takakura","year":"2010","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.omton.2025.201100_bib160","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-025-01691-5","article-title":"The cGAS\u2012STING pathway in cancer immunity: mechanisms, challenges, and therapeutic implications","volume":"18","author":"Shen","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omton.2025.201100_bib161","article-title":"Oncolytic vesicular stomatitis virus alone or in combination with JAK inhibitors is effective against ovarian cancer","volume":"32","author":"Geoffroy","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.omton.2025.201100_bib162","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1016\/j.apsb.2024.03.007","article-title":"Pharmacokinetic enhancement of oncolytic virus M1 by inhibiting JAK\u2012STAT pathway","volume":"14","author":"Tan","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.omton.2025.201100_bib163","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3390\/onco4040022","article-title":"Cancer Immunotherapy: Targeting TREX1 Has the Potential to Unleash the Host Immunity against Cancer Cells","volume":"4","author":"Hawillo","year":"2024","journal-title":"Onco"},{"key":"10.1016\/j.omton.2025.201100_bib164","first-page":"183","article-title":"Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy","volume":"4","author":"Nakashima","year":"2015","journal-title":"Oncolytic Virother."},{"key":"10.1016\/j.omton.2025.201100_bib165","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12985-025-02672-3","article-title":"Development of attenuated Orf virus as a safe oncolytic viral vector for nasopharyngeal carcinoma treatment","volume":"22","author":"Yamada","year":"2025","journal-title":"Virol. J."},{"key":"10.1016\/j.omton.2025.201100_bib166","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1494887","article-title":"Comparison of differences in immune cells and immune microenvironment among different kinds of oncolytic virus treatments","volume":"15","author":"Wu","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2025.201100_bib167","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.3390\/ijms26051988","article-title":"Mechanisms and strategies to overcome drug resistance in colorectal cancer","volume":"26","author":"Haynes","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omton.2025.201100_bib168","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.3390\/vaccines12091010","article-title":"Dose Considerations for Vaccinia Oncolytic Virus Based on Retrospective Reanalysis of Early and Late Clinical Trials","volume":"12","author":"Cyrelle Ornella","year":"2024","journal-title":"Vaccines"},{"key":"10.1016\/j.omton.2025.201100_bib169","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103362","article-title":"Comparative safety and efficacy of oncolytic virotherapy for the treatment of individuals with malignancies: a systematic review, meta-analysis, and Bayesian network meta-analysis","volume":"86","author":"Lau","year":"2025","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.omton.2025.201100_bib170","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41392-023-01522-4","article-title":"Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.omton.2025.201100_bib171","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3390\/cancers10060160","article-title":"A phase II study of pelareorep (REOLYSIN\u00ae) in combination with gemcitabine for patients with advanced pancreatic adenocarcinoma","volume":"10","author":"Mahalingam","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.omton.2025.201100_bib172","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.3390\/cancers12051210","article-title":"Advantages of using paclitaxel in combination with oncolytic adenovirus utilizing RNA destabilization mechanism","volume":"12","author":"Hossain","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.omton.2025.201100_bib173","first-page":"231","article-title":"A randomized phase II study of FOLFOX6\/bevacizumab with or without pelareorep in patients with metastatic colorectal cancer: IND. 210, a Canadian Cancer Trials Group Trial","volume":"17","author":"Jonker","year":"2018","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.omton.2025.201100_bib174","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.3390\/ijms20051125","article-title":"Cisplatin synergistically enhances antitumor potency of conditionally replicating adenovirus via p53 dependent or independent pathways in human lung carcinoma","volume":"20","author":"Ali","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omton.2025.201100_bib175","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/78638","article-title":"A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer","volume":"6","author":"Khuri","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2025.201100_bib176","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000981","article-title":"Enhanced immunotherapeutic profile of oncolytic virus-based cancer vaccination using cyclophosphamide preconditioning","volume":"8","author":"Pol","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2025.201100_bib177","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113986","article-title":"Virotherapy: From single agents to combinatorial treatments","volume":"177","author":"Malfitano","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.omton.2025.201100_bib178","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1172\/JCI121323","article-title":"Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival","volume":"129","author":"Kellish","year":"2019","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omton.2025.201100_bib179","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113481","article-title":"Synergistic Anti-Tumor Effects of Newcastle Disease Virus and Doxorubicin: Evidence from A Murine Breast Cancer Model","volume":"143","author":"Sabri","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.omton.2025.201100_bib180","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.3390\/cancers12082178","article-title":"Immunoradiotherapy as an effective therapeutic strategy in lung cancer: From palliative care to curative intent","volume":"12","author":"Chicas-Sett","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.omton.2025.201100_bib181","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3389\/fonc.2017.00153","article-title":"Combining oncolytic adenovirus with radiation\u2014a paradigm for the future of radiosensitization","volume":"7","author":"O\u2019Cathail","year":"2017","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2025.201100_bib182","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1158\/1541-7786.MCR-19-0836","article-title":"Radiation attenuates prostate tumor antiviral responses to vesicular stomatitis virus containing IFN\u03b2, resulting in pronounced antitumor systemic immune responses","volume":"18","author":"Udayakumar","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.omton.2025.201100_bib183","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.790150","article-title":"Oncolytic virotherapy: From bench to bedside","volume":"9","author":"Yang","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.omton.2025.201100_bib184","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1089\/hum.2020.101","article-title":"Design and rationale for first-in-human phase 1 immunovirotherapy clinical trial of oncolytic HSV G207 to treat malignant pediatric cerebellar brain tumors","volume":"31","author":"Bernstock","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omton.2025.201100_bib185","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.omto.2023.03.003","article-title":"oHSV-P10 reduces glioma stem cell enrichment after oncolytic HSV therapy","volume":"29","author":"Sahu","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omton.2025.201100_bib186","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216169","article-title":"Radiation combined with oncolytic vaccinia virus provides pronounced antitumor efficacy and induces immune protection in an aggressive glioblastoma model","volume":"562","author":"Storozynsky","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.omton.2025.201100_bib187","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1089\/humc.2017.002","article-title":"Rationale and design of a phase 1 clinical trial to evaluate HSV G207 alone or with a single radiation dose in children with progressive or recurrent malignant supratentorial brain tumors","volume":"28","author":"Waters","year":"2017","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.omton.2025.201100_bib188","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1158\/1078-0432.CCR-16-3232","article-title":"Phase I trial of intravenous oncolytic vaccinia virus (GL-ONC1) with cisplatin and radiotherapy in patients with locoregionally advanced head and neck carcinoma","volume":"23","author":"Mell","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2025.201100_bib189","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1158\/1078-0432.CCR-17-1717","article-title":"Combinatorial effects of VEGFR kinase inhibitor axitinib and oncolytic virotherapy in mouse and human glioblastoma stem-like cell models","volume":"24","author":"Saha","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2025.201100_bib190","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/mt.2011.39","article-title":"Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy","volume":"19","author":"Heo","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2025.201100_bib191","doi-asserted-by":"crossref","first-page":"5839","DOI":"10.1158\/1078-0432.CCR-16-0143","article-title":"Repurposing sunitinib with oncolytic reovirus as a novel immunotherapeutic strategy for renal cell carcinoma","volume":"22","author":"Lawson","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2025.201100_bib192","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.omto.2022.04.006","article-title":"Inhibition of MEK-ERK pathway enhances oncolytic vaccinia virus replication in doxorubicin-resistant ovarian cancer","volume":"25","author":"Lee","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omton.2025.201100_bib193","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41417-018-0074-6","article-title":"JAK\/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models","volume":"26","author":"Patel","year":"2019","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.omton.2025.201100_bib194","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0014462","article-title":"Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors","volume":"5","author":"MacTavish","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.omton.2025.201100_bib195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0092919","article-title":"Histone deacetylase inhibitors improve the replication of oncolytic herpes simplex virus in breast cancer cells","volume":"9","author":"Cody","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.omton.2025.201100_bib196","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/imcb.12723","article-title":"Tissue biomarkers of immune checkpoint inhibitor therapy","volume":"102","author":"Davoudi","year":"2024","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.omton.2025.201100_bib197","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3389\/fimmu.2020.00683","article-title":"Combining oncolytic viruses with cancer immunotherapy: establishing a new generation of cancer treatment","volume":"11","author":"Shi","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2025.201100_bib198","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3390\/cancers12030738","article-title":"Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.omton.2025.201100_bib199","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","article-title":"Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity","volume":"52","author":"Lee","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.omton.2025.201100_bib200","series-title":"Seminars in Oncology","article-title":"The next hurdle in cancer immunotherapy: overcoming the non\u2013T-cell\u2013inflamed tumor microenvironment","author":"Gajewski","year":"2015"},{"key":"10.1016\/j.omton.2025.201100_bib201","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ccell.2017.07.012","article-title":"A viro-immunotherapy triple play for the treatment of glioblastoma","volume":"32","author":"Bell","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2025.201100_bib202","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/gt.2011.176","article-title":"Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4","volume":"19","author":"Dias","year":"2012","journal-title":"Gene Ther."},{"key":"10.1016\/j.omton.2025.201100_bib203","doi-asserted-by":"crossref","first-page":"226ra32","DOI":"10.1126\/scitranslmed.3008095","article-title":"Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy","volume":"6","author":"Zamarin","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omton.2025.201100_bib204","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.102020","article-title":"The Oncolytic virus VT1092M and an Anti-PD-L1 antibody synergize to induce systemic antitumor immunity in a murine bilateral tumor model","volume":"46","author":"Zhu","year":"2024","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.omton.2025.201100_bib205","doi-asserted-by":"crossref","DOI":"10.1016\/j.omto.2023.100729","article-title":"Breaking the barriers in cancer care: The next generation of herpes simplex virus-based oncolytic immunotherapies for cancer treatment","volume":"31","author":"Khushalani","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omton.2025.201100_bib206","doi-asserted-by":"crossref","first-page":"9527","DOI":"10.1200\/JCO.2023.41.16_suppl.9527","article-title":"Preliminary safety and efficacy results from an open-label, multicenter, phase 1 study of RP2 as a single agent and in combination with nivolumab in a cohort of patients with uveal melanoma","volume":"41","author":"Sacco","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2025.201100_bib207","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/2326-6066.CIR-19-0628","article-title":"Intratumoral delivery of a PD-1\u2013blocking scFv encoded in oncolytic HSV-1 promotes antitumor immunity and synergizes with TIGIT blockade","volume":"8","author":"Lin","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omton.2025.201100_bib208","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111579","article-title":"A dual-functional oncolytic adenovirus ZD55-aPD-L1 scFv armed with PD-L1 inhibitor potentiates its antitumor activity","volume":"128","author":"Mei","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.omton.2025.201100_bib209","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/s41417-021-00389-3","article-title":"Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model","volume":"29","author":"Zhang","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.omton.2025.201100_bib210","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006270","article-title":"Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial","volume":"11","author":"Chesney","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2025.201100_bib211","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/neuonc\/noad052","article-title":"Polio virotherapy targets the malignant glioma myeloid infiltrate with diffuse microglia activation engulfing the CNS","volume":"25","author":"Yang","year":"2023","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.omton.2025.201100_bib212","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.cell.2018.07.035","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"174","author":"Ribas","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.omton.2025.201100_bib213","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3390\/biomedicines13010098","article-title":"Advances in cell and immune therapies for melanoma","volume":"13","author":"Timis","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.omton.2025.201100_bib214","article-title":"Combination therapy with oncolytic viruses for lung cancer treatment","volume":"15","author":"Sun","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2025.201100_bib215","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1634\/theoncologist.2019-0233","article-title":"The European medicines agency review of Kymriah (Tisagenlecleucel) for the treatment of acute lymphoblastic leukemia and diffuse large B-cell lymphoma","volume":"25","author":"Ali","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.omton.2025.201100_bib216","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1634\/theoncologist.2019-0646","article-title":"EMA review of axicabtagene ciloleucel (Yescarta) for the treatment of diffuse large B-cell lymphoma","volume":"25","author":"Papadouli","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.omton.2025.201100_bib217","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/bjh.17419","article-title":"Mantle cell lymphoma\u2013advances in molecular biology, prognostication and treatment approaches","volume":"195","author":"Silkenstedt","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.omton.2025.201100_bib218","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1007\/s00262-021-02856-0","article-title":"Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma","volume":"70","author":"Huang","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omton.2025.201100_bib219","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41576-021-00329-9","article-title":"Genetic engineering of T cells for immunotherapy","volume":"22","author":"Ellis","year":"2021","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.omton.2025.201100_bib220","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1158\/2326-6066.CIR-17-0314","article-title":"Improving CART-cell therapy of solid tumors with oncolytic virus\u2013driven production of a bispecific T-cell engager","volume":"6","author":"Wing","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omton.2025.201100_bib221","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz1863","article-title":"Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors","volume":"12","author":"Park","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omton.2025.201100_bib222","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00262-024-03757-8","article-title":"Systemic delivery of oncolytic herpes virus using CAR-T cells enhances targeting of antitumor immuno-virotherapy","volume":"73","author":"Zhang","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omton.2025.201100_bib223","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99573","article-title":"Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses","volume":"3","author":"Watanabe","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.omton.2025.201100_bib224","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1016\/j.ymthe.2017.09.010","article-title":"Adenovirotherapy delivering cytokine and checkpoint inhibitor augments CAR T cells against metastatic head and neck cancer","volume":"25","author":"Rosewell Shaw","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2025.201100_bib225","doi-asserted-by":"crossref","DOI":"10.4161\/21505594.2014.988098","article-title":"Oncolytic virus expressing RANTES and IL-15 enhances function of CAR-modified T cells in solid tumors","volume":"4","author":"Nishio","year":"2015","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omton.2025.201100_bib226","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ymthe.2022.08.021","article-title":"CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma","volume":"31","author":"Wang","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2025.201100_bib227","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13045-021-01084-4","article-title":"Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies","volume":"14","author":"Tian","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omton.2025.201100_bib228","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3390\/biomedicines8070204","article-title":"Bi-and tri-specific T cell engager-armed oncolytic viruses: next-generation cancer immunotherapy","volume":"8","author":"Guo","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.omton.2025.201100_bib229","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.drudis.2015.02.008","article-title":"Bispecific antibodies","volume":"20","author":"Kontermann","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.omton.2025.201100_bib230","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1080\/17474086.2018.1540928","article-title":"Current and future role of bispecific T-cell engagers in pediatric acute lymphoblastic leukemia","volume":"11","author":"Algeri","year":"2018","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.omton.2025.201100_bib231","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/mt.2013.240","article-title":"T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy","volume":"22","author":"Yu","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2025.201100_bib232","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1158\/0008-5472.CAN-16-1708","article-title":"Oncolytic adenoviral delivery of an EGFR-targeting T-cell engager improves antitumor efficacy","volume":"77","author":"Fajardo","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2025.201100_bib233","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41408-022-00634-4","article-title":"CD19-targeted BiTE expression by an oncolytic vaccinia virus significantly augments therapeutic efficacy against B-cell lymphoma","volume":"12","author":"Lei","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.omton.2025.201100_bib234","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2096362","article-title":"Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer","volume":"11","author":"Wang","year":"2022","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omton.2025.201100_bib235","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3390\/v14030525","article-title":"Cytolytic properties and genome analysis of Rigvir\u00ae Oncolytic Virotherapy virus and other Echovirus 7 Isolates","volume":"14","author":"Hietanen","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.omton.2025.201100_bib236","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2147\/OV.S196403","article-title":"Preclinical and clinical development of oncolytic adenovirus for the treatment of malignant glioma","volume":"8","author":"Kiyokawa","year":"2019","journal-title":"Oncolytic Virother."},{"key":"10.1016\/j.omton.2025.201100_bib237","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3389\/fonc.2017.00106","article-title":"Immune system, friend or foe of oncolytic virotherapy?","volume":"7","author":"Filley","year":"2017","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2025.201100_bib238","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1172\/JCI122287","article-title":"Oncolytic viruses: overcoming translational challenges","volume":"129","author":"Martinez-Quintanilla","year":"2019","journal-title":"J. Clin. Investig."}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329925001699?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329925001699?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T01:21:07Z","timestamp":1772155267000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329925001699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":238,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2950329925001699"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2025.201100","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Viral warriors: Unlocking the immune system\u2019s potential with oncolytic viruses in cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2025.201100","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201100"}}